Genomics Heads Back to Basics in 2001, Analyst Says | GenomeWeb

SAN FRANCISCO, Jan 8 – Investors are expected to take a “back to basics” approach to genomics during 2001 as they seek companies that are generating revenues from fully developed technologies, Rob Olan, a life science technology analyst at JP Morgan H&Q, said Monday. 

“In general, the atmosphere is going to be less euphoric,” Olan told GenomeWeb at the start of the JP Morgan H&Q healthcare conference. “Companies that are more established will do better.” 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.